ArticleFrontiers in oncology2019
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.Breast cancer (Tokyo, Japan) · 2025Observational
- Illuminating Bilateral Breast Cancer: A Multicenter Experience and Clinical Observations.Medicina (Kaunas, Lithuania) · 2025Article
- Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor‑positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Multicenter and Retrospective Study.Breast cancer (Dove Medical Press) · 2025Article
- Combining Molecular and Traditional Prognostic Factors: A Holistic Approach to Breast Cancer Prognostication.Diagnostics (Basel, Switzerland) · 2024Article
- Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).Breast cancer (Tokyo, Japan) · 2023Article
- Mammary Glands of Women, Female Dogs and Female Rats: Similarities and Differences to Be Considered in Breast Cancer Research.Veterinary sciences · 2023Review
- Deep neural networks with knockoff features identify nonlinear causal relations and estimate effect sizes in complex biological systems.GigaScience · 2022Article
- Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.Molecular oncology · 2022Article
- Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer.NPJ breast cancer · 2021Article
- Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.The oncologist · 2020Article
- Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.Frontiers in oncology · 2019Review
- The Role of the NOLUS Score in Predicting pCR and iDFS in HR-positive HER2-negative Early Breast Cancer Patients who Received Neoadjuvant Chemotherapy.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.